Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 19/20 | 0.52 |
| ▸ | ADRB1 | P08588 | 10/20 | 0.52 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5437983 | 0.94 | ADRB2 (0.56) | ADRB2ADRB1ADRB3SLC6A4SLC6A3 | |
| SCHEMBL5437980 | 0.94 | ADRB2 (0.56) | ADRB2ADRB1ADRB3SLC6A4SLC6A3 | |
| SCHEMBL5280018 | 0.93 | ADRB2 (0.50) | ADRB2ADRB1ADRB3 | |
| SCHEMBL5285826 | 0.93 | ADRB2 (0.56) | ADRB2ADRB1ADRB3 | |
| SCHEMBL5284583 | 0.92 | ADRB2 (0.57) | ADRB2ADRB1ADRB3 | |
| SCHEMBL5292149 | 0.89 | ADRB2 (0.49) | ADRB2ADRB1ADRB3 | |
| SCHEMBL5283191 | 0.89 | ADRB2 (0.48) | ADRB2ADRB1ADRB3 | |
| SCHEMBL5421813 | 0.89 | ADRB3 (0.53) | ADRB2ADRB1ADRB3 | |
| SCHEMBL5283600 | 0.89 | ADRB3 (0.53) | ADRB2ADRB1ADRB3 | |
| SCHEMBL5278128 | 0.89 | ADRB2 (0.48) | ADRB2ADRB1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1497261-B1 | PHENETHANOLAMINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2007-12-19 | — | — | EP | disclosed |
| US-7271197-B2 | Phenethanolamine derivatives | GLAXO GROUP LIMITED (GB) | 2007-09-18 | — | — | US | disclosed |
| US-20050256201-A1 | Phenethanolamine derivatives | GLAXO GROUP LIMITED | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256201-A1 | Phenethanolamine derivatives | PNMT, PHOSPHO1, NAPEPLD | ADRB2 85/4885ADRB1 148/4885ADRB3 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.